open access
[18F]FDG PET/CT and CA-125 in the evaluation of ovarian cancer relapse or persistence: is there any correlation?
, 1, 1, 1
Affiliations- Nuclear Medicine, Spedali Civili Brescia, Brescia, Italy
open access
Abstract
Background: Ovarian cancer relapse can be diagnosed by serum tumor markers measurements and 18F-fluorodoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) findings. The aim of our study was to analyze the potential relationship between cancer antigen 125 (CA-125) and PET/CT results in patients affected by ovarian cancer. Material and methods: Ninety-two [18F]FDG PET/CT scans in sixty-one patients with diagnosis of ovarian cancer were analyzed and compared to CA-125 values. PET/CT results were compared to other imaging modalities, histology or follow-up data in order to define its diagnostic accuracy. PET/CT studies were analyzed qualitatively and semiquantitatively by measuring the maximum and mean standardized uptake value body weight max (SUVbw max, SUVbw mean), maximum SUV lean body mass (SUVlbm), maximum SUV body surface area (SUVbsa), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of hypermetabolic lesions. All measurements were compared with CA-125 values. Results: Twenty PET/CT studies were true negative, sixty-three true positive, five false positive and four false negative with sensitivity of 94%, specificity of 80%, negative predictive value of 83%, positive predictive value of 93% and accuracy of 90%. CA-125 levels were significantly correlated with PET/CT results and all PET/CT semiquantitative parameters. CA-125 cutoff values of 17 UI/mL is the best compromise between sensitivity and specificity in discriminating between positive and negative PET/CT result. Conclusions: [18F]FDG PET/CT has good accuracy in evaluating patients with relapse or persistance of ovarian cancer. CA-125 levels were significantly correlated with metabolic PET/CT parameters.
Abstract
Background: Ovarian cancer relapse can be diagnosed by serum tumor markers measurements and 18F-fluorodoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) findings. The aim of our study was to analyze the potential relationship between cancer antigen 125 (CA-125) and PET/CT results in patients affected by ovarian cancer. Material and methods: Ninety-two [18F]FDG PET/CT scans in sixty-one patients with diagnosis of ovarian cancer were analyzed and compared to CA-125 values. PET/CT results were compared to other imaging modalities, histology or follow-up data in order to define its diagnostic accuracy. PET/CT studies were analyzed qualitatively and semiquantitatively by measuring the maximum and mean standardized uptake value body weight max (SUVbw max, SUVbw mean), maximum SUV lean body mass (SUVlbm), maximum SUV body surface area (SUVbsa), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of hypermetabolic lesions. All measurements were compared with CA-125 values. Results: Twenty PET/CT studies were true negative, sixty-three true positive, five false positive and four false negative with sensitivity of 94%, specificity of 80%, negative predictive value of 83%, positive predictive value of 93% and accuracy of 90%. CA-125 levels were significantly correlated with PET/CT results and all PET/CT semiquantitative parameters. CA-125 cutoff values of 17 UI/mL is the best compromise between sensitivity and specificity in discriminating between positive and negative PET/CT result. Conclusions: [18F]FDG PET/CT has good accuracy in evaluating patients with relapse or persistance of ovarian cancer. CA-125 levels were significantly correlated with metabolic PET/CT parameters.
Keywords
PET/CT; ovarian cancer; tumor markers; CA-125
About this articleTitle
[18F]FDG PET/CT and CA-125 in the evaluation of ovarian cancer relapse or persistence: is there any correlation?
Journal
Issue
Article type
Research paper
Pages
78-84
Published online
2022-06-21
Page views
4433
Article views/downloads
969
DOI
Pubmed
Bibliographic record
Nucl. Med. Rev 2022;25(2):78-84.
Keywords
PET/CT
ovarian cancer
tumor markers
CA-125
Authors
Francesco Dondi
Domenico Albano
Francesco Bertagna
Raffaele Giubbini
References (25)- Marzola MC, Chondrogiannis S, Rubello D. Fludeoxyglucose F 18 PET/CT Assessment of Ovarian Cancer. PET Clin. 2018; 13(2): 179–202.
- Colombo N, Sessa C, Bois Adu, et al. ESMO–ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019 [Epub ahead of print].
- Forstner R. Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol. 2007; 17(12): 3223–3235.
- Signorelli M, Guerra L, Pirovano C, et al. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study. Gynecol Oncol. 2013; 131(2): 395–399.
- Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009; 71(1): 164–174.
- Kim TH, Kim J, Kang YK, et al. Identification of Metabolic Biomarkers Using Serial F-FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian Cancer. Transl Oncol. 2017; 10(3): 297–303.
- Antunovic L, Cimitan M, Borsatti E, et al. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities. Clin Nucl Med. 2012; 37(8): e184–e188.
- Goonewardene TI, Hall MR, Rustin GJS. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007; 8(9): 813–821.
- Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996; 14(5): 1545–1551.
- Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005; 23(36): 9338–9343.
- Ghosh J, Thulkar S, Kumar R, et al. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study. Natl Med J India. 2013; 26(6): 327–331.
- Boellaard R, Delgado-Bolton R, Oyen WJG, et al. European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42(2): 328–354.
- Limei Z, Yong C, Yan Xu, et al. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2013; 23(4): 598–607.
- Ebina Y, Watari H, Kaneuchi M, et al. Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer. Eur J Nucl Med Mol Imaging. 2014; 41(3): 446–451.
- Soussan M, Wartski M, Cherel P, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol. 2008; 108(1): 160–165.
- Palomar A, Nanni C, Castellucci P, et al. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imaging Biol. 2012; 14(1): 123–129.
- Menzel C, Döbert N, Hamscho N, et al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol. 2004; 180(8): 497–501.
- Thrall MM, DeLoia JA, Gallion H, et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007; 105(1): 17–22.
- Suppiah S, Chang WL, Hassan HA, et al. Systematic Review on the Accuracy of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance Imaging in the Management of Ovarian Cancer: Is Functional Information Really Needed? World J Nucl Med. 2017; 16(3): 176–185.
- Mainguené C, Aillet G, Kremer M, et al. Immunohistochemical study of ovarian tumors using the OC 125 monoclonal antibody as a basis for potential in vivo and in vitro applications. J Nucl Med Allied Sci. 1986; 30(1): 19–22.
- Kim CY, Jeong SY, Chong GOh, et al. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol. 2015; 136(3): 498–504.
- Han LY, Karavasilis V, Hagen Tv, et al. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Eur J Cancer. 2010; 46(8): 1359–1364.
- Varughese E, Kondalsamy-Chennakesavan S, Obermair A. The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study. J Ovarian Res. 2012; 5: 11.
- Evangelista L, Palma MD, Gregianin M, et al. Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. J Turk Ger Gynecol Assoc. 2015; 16(3): 137–144.
- Fularz M, Adamiak P, Czepczyński R, et al. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level. Nuklearmedizin. 2015; 54(4): 158–162.
